臨床研究支援事業

成果一覧

CSPOR

乳癌

POTENT

Lancet Oncol . 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9

Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial Masakazu Toi , Shigeru Imoto , Takanori Ishida , Yoshinori Ito , Hiroji Iwata , Norikazu Masuda , Hirofumi Mukai , Shigehira Saji , Akira Shimizu , Takafumi Ikeda , Hironori Haga , Toshiaki Saeki , Kenjiro Aogi , Tomoharu Sugie , Takayuki Ueno , Takayuki Kinoshita , Yuichiro Kai , Masahiro Kitada , Yasuyuki Sato , Kenjiro Jimbo , Nobuaki Sato , Hiroshi Ishiguro , Masahiro Takada , Yasuo Ohashi , Shinji Ohno


肺癌

LC05 (JP-CLEAR)

Japanese Journal of Clinical Oncology, Volume 49, Issue 6, June 2019, Pages 554–558,

Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial) (臼井 一裕:NTT東日本関東病院)




CSP-A-TOP

J-05

JOINT-05

J Bone Miner Metab ; 2020, 38, 412–417.

Design of a randomized trial of teriparatide followed by alendronate:Japanese Osteoporosis Intervention Trial‑05 (JOINT‑05). Tanaka S, Mori S, Hagino H, Sugimoto T


J-04

JOINT-04

J Bone Miner Metab; 2021 Mar 18. doi: 10.1007/s00774-021-01208-3. Online ahead of print.

Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study.Hiroshi Hagino , Yukari Uemura , Satoshi Mori , Teruki Sone , Hiroaki Ohta , Toshitaka Nakamura

Curr Med Res Opin; 2020,36(11),1847-1859. doi: 10.1080/03007995.2020.1816537. Epub 2020 Sep 14

Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04. Yukari Uemura , Teruki Sone , Shiro Tanaka , Teruhiko Miyazaki , Mayumi Tsukiyama , Akira Taguchi , Satoshi Soen , Satoshi Mori , Hiroshi Hagino , Toshitsugu Sugimoto , Masao Fukunaga , Hiroaki Ohta , Toshitaka Nakamura , Hajime Orimo , Masataka Shiraki , Adequate Treatment of Osteoporosis (A-TOP) Research Group

J Bone Miner Metab ; 2019,37, 886–892.

Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid. Taguchi A, Uemura Y, Imai T, Tanaka S, Ohta H, Nakamura T, Orimo H, Sugimoto T, Soen S, Shiraki M ,Adequate Treatment of Osteoporosis(A-TOP) research group.

J Bone Miner Metab; 2019,37(3),491-495. doi: 10.1007/s00774-018-0942-z. Epub 2018 Jul 17.

Study design of multi-center, open-label randomized controlled, head-to-headtrial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04. Uemura Y, Tanaka S, Miyazaki T, Tsukiyama M, Sone T, Taguchi A, Soen S, Moei S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M, Adequate Treatment of Osteoporosis (A-TOP) research group.


J-03

JOINT-03

Osteoporos Int; 2017,28(6),1893-1901.DOI 10,1007/S 00198-017-3966-7

Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial. Imai T, Tanaka S, Kawakami K, Miyazaki T, Hagino H, Shiraki M, for the A-TOP(Adequate Treatment of Osteoporosis) Research Group.

J Bone Miner Metab ; 2017,35(4);385-395.DOI 10.1007/s00774-016-0768-5

Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03. Tanaka S, Miyazaki T, Uemura Y, Miyakawa N, Gorai I, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M.

J Bone Miner Metab; 2014,32(3), 298-304.

Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03). Tanaka S, Miyazaki T, Uemura Y, Kuroda T, Miyakawa N, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki


J-02

JOINT-02

J Orthop Sci. ; 2020,S0949-2658(20)30332-8.

Impact of bone mineral density in reducing fracture risk in patients receiving alendronate plus alfacalcidol therapy. Eiji Itoi , Yukari Uemura , Hiroaki Ohta , Toshitaka Nakamura , Masao Fukunaga , Hajime Orimo , Masataka Shiraki .

Clin Therap; 2014,36(2),225-235.

Serum 25 hydroxyvitamin D level as an independent determinant of quality of life in osteoporosis with high risk for fracture. Ohta H, Uemura Y, Nakamura T, Fukunaga M, Ohashi Z, Hosoi T, Mori S, Sugimoto T, Itoi E, Orimo H, Shiraki M for the Adequate Treatment of Osteoporosis.(A-TOP)research group.

J Bone Miner Metab; 2015,33(6):,642-650.

Comparison of expert and nonexpert physicians in the assessment of vertebral fractures using the semiquantitative method in Japan. Uemura Y, Miyakawa N, Orimo H, Shiraki M, Nakamura T, Mori S.

Curr Med Res Opin; 2011,27(6),1273-84.

Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT)- 02. Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M; A-TOP (Adequate Treatment of Osteoporosis)research group

J Bone Miner Metab; 2011,29(1),37-43.

Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial(JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP). Shiraki M, Kuroda T, Hosoi T, Ohashi Y, Ohta H, Fukunaga M, Nakamura T, Orimo H et al.


A-01

JOB

Jpn J Pharmacoepidemiol;21(1);13-19,2016,DOI.org/10.3820/jjpe.21.13

Validation Study of Claims-based Definitions of Suspected Atypical Femoral Fractures Using Clinical Information. Tanaka S, Hagino H, Ishizuka A, Miyazaki T, Yamamoto T, Hosoi T.


CSP-LD






LD-09

REAL-CAD

American Heart Association(AHA)_ Late breaking/ 2017年11月13日

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Takeshi Kimura, Teruo Inoue, Isao Taguchi, Hiroshi Iwata, Satoshi Iimuro, Takafumi Hiro, Yoshihisa Nakagawa, Yukio Ozaki, Yasuo Ohashi, Hiroyuki Daida, Hiroaki Shimokawa, Ryozo Nagai, on behalf of the REAL-CAD Study Investigators


LD-08

EWTOPIA75

American Heart Association(AHA)_Late breaking/2018年11月10日

Ezetimibe in Prevention of Cerebro- and Cardiovascular Events in Middle- to High-Risk, Elderly (75 Years Old or Over) Patients With Elevated LDL-Cholesterol.
 Yasuyoshi Ouchi , Hidenori Arai, Jun Sasaki, Koutaro Yokote, Masanari Kuwabara, Kazumasa Harada, Takumi Imai, Shiro Tanaka, Yasuo Ohashi, Hideki Ito on behalf of the EWTOPIA investigators





疫学調査

JEDAS Study

米国糖尿病学会 ニューオリンズ・2009年6月

JEDAS研究第2報 / 田中俊一 / 医療法人金沢内科クリニック


CSP-HOR

CSP-CCR

C-10

子宮がん予防意識調査

第66回日本産科婦人科学会学術講演会/2014

子宮頸がん予防に対する女性医療従事者の意識調査・入江琢也


C-09

J-HERS4

日本性感染症学会誌 2013; 24(1): 103-9/2013

尖圭コンジローマ患者のQOL調査:多施設共同研究 (J-HERS Study)・入江, et al.

第65回 日本産科婦人科学会学術講演会/2013

尖圭コンジローマに罹患した日本人女性のQuolity of Life (QOL) 調査: 多施設共同研究 (J-HERS Study)・伊藤富士子

第25回 日本性感染症学会学術大会/2012

尖圭コンジローマ患者のQOL調査・入江琢也

28th International Papillomavirus Conference (IPV)/2012

Multi-Center Study (J-HERS) for Quality of Life of Women with Genital Warts in Japan -Interim Report-・F Ito


C-08

J-HERS3

第52回 日本臨床細胞学会 秋季大会/2013

日本における高リスク型HPVを再考する・伊藤富士子

第54回 日本臨床細胞学会総会 春季大会/2013

子宮頚部細胞診とHPV感染および型別診断の大規模研究:J-HERS多施設共同研究・前濱俊之

第54回 日本臨床細胞学会総会 春季大会/2013

子宮頚部液状細胞診とHPV-DNA検査併用の意義:J-HERS大規模調査・笹川寿之

第65回 日本産科婦人科学会学術講演会/2013

日本人女性の子宮頚部に感染するHPV型と細胞診談の大規模研究:多施設共同研究 (J-HERS Study)・前濱俊之

第25回 日本性感染症学会学術大会/2012

HPV DNA型調査・前濱俊之

28th International Papillomavirus Conference (IPV)/2012

A multii-center study (J-HERS) for prevalent HPV genotypes and abnormal cytology in young Japanese women・T Sasagawa


C-06

J-HERS1

27th International Papillomavirus Conference (IPV)/2011

Estimation of the incidence of genital wart, cervical intraepithelial neoplasia and cervical cancer in Japan (J-HERS)・T Sasagawa


C-05

COPD研究

日本呼吸器学会/2014

呼吸器疾患未治療の日本人COPD患者に対するガイドライン薬物治療効果の検討・瀬戸口靖弘(東京医科大学病院)


その他